1-3 of 3
Alicia Orellana, MD MPH
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Amylou C. Dueck, PhD, John Mascarenhas, MD, Heidi Elizabeth Kosiorek, MS, Abdulraheem Yacoub, MD, Josef T. Prchal, MD, Dmitriy Berenzon, MD, Maria R. Baer, MD, Ellen K Ritchie, MD, Richard T Silver, MD, Craig M. Kessler, MD, Elliott F. Winton, MD, Maria Chiara Finazzi, MD, Alessandro Rambaldi, MD Prof, Alessandro M. Vannucchi, David S. Leibowitz, MD, Damiano Rondelli, MD, Murat O. Arcasoy, MD, Rosalind Catchatourian, MD, Joseph Vadakara, MBBS, Vittorio Rosti, MD, Elizabeth Hexner, MDMS, Marina Kremyanskaya, MD PhD, Alicia Orellana, MD MPH, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, PhD, Mohamed E. Salama, MD, Rona Singer Weinberg, PhD, Raajit K. Rampal, MD PhD, Ronald Hoffman, MD, Ruben A Mesa, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4206.
https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206
Published: 2017
Journal Articles

Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia

John Mascarenhas, MD, Min Lu, PhDMD, Elizabeth Virtgaym, Heidi Kosiorek, MS, Marina Stal, Lonette Sandy, Alicia Orellana, MD MPH, Lijuan Xia, Marina Kremyanskaya, MD PhD, Bruce Petersen, MD, Amylou Dueck, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 254.
https://doi.org/10.1182/blood.V130.Suppl_1.254.254
Published: 2017
Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Abdulraheem Yacoub, MD, John Mascarenhas, MD, Heidi Elizabeth Kosiorek, MS, Josef T. Prchal, MD, Dmitriy Berenzon, MD, Maria R. Baer, MD, Ellen K Ritchie, MD, Richard T Silver, MD, Craig M. Kessler, MD, Elliott F. Winton, MD, Maria Chiara Finazzi, MD, Alessandro Rambaldi, MD Prof, Alessandro M. Vannucchi, David S. Leibowitz, MD, Damiano Rondelli, MD, Murat O. Arcasoy, MD, Rosalind Catchatourian, MD, Joseph Vadakara, MBBS, Vittorio Rosti, MD, Elizabeth Hexner, MDMS, Marina Kremyanskaya, MD PhD, Alicia Orellana, MD MPH, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, PhD, Mohamed E. Salama, MD, Rona Singer Weinberg, PhD, Raajit K. Rampal, MD PhD, Ruben A Mesa, MD, Judith D Goldberg, ScD, Amylou C. Dueck, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 321.
https://doi.org/10.1182/blood.V130.Suppl_1.321.321
Published: 2017